Trial Profile
Phase II trial of NNZ 2566 for autism spectrum disorders and neurodevelopmental disorders.
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2012
Price :
$35
*
At a glance
- Drugs Trofinetide (Primary)
- Indications Developmental disabilities; Neurodevelopmental disorders; Pervasive child development disorders
- Focus Therapeutic Use
- Sponsors Neuren Pharmaceuticals
- 07 Dec 2012 New trial record